Resistance to Ciprofloxacin and the New Fluoroquinolones
Peter M. Hawkey
Abstract
Peter M. Hawkey
Abstract
Resistance to ciprofloxacin has generally remained low in the UK. A low rate of resistance development in vitro has been suggested for the newer fluoroquinolones such as grepafloxacin and trovafloxacin. Levofloxacin is likely to have a pattern of development of resistance similar to that of ofloxacin. Resistance problems with ofloxacin are being reported in the USA, but it is unclear whether similar problems will arise with levofloxacin. Restrained quinolone use, surveillance of pathogen susceptibility and control of cross-infection with resistant clones remain important strategies for managing fluoroquinolone resistance.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Resistance to ciprofloxacin has generally remained low in the UK. A low rate of resistance development in vitro has been suggested for the newer fluoroquinolones such as grepafloxacin and trovafloxacin. Levofloxacin is likely to have a pattern of development of resistance similar to that of ofloxacin. Resistance problems with ofloxacin are being reported in the USA, but it is unclear whether similar problems will arise with levofloxacin. Restrained quinolone use, surveillance of pathogen susceptibility and control of cross-infection with resistant clones remain important strategies for managing fluoroquinolone resistance.
Key concepts: Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin, Quinolone, Antibacterial agent, Microbiology, Pathogen